From another perspective, since EGFR aberrations co-occurred with other genetic assaults, developing a potent c-MET/EGFR inhibitor with multi-target potential capable of inhibiting multiple pathways with minimal side effects may open up new windows for long-lasting, multilayer control of CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.